{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:03Z","timestamp":1760146863598,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Background: Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce. Methods: This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G&gt;A, G551D) undergoing off-label ETI therapy. Evaluations were conducted at 0, 3, 6, 9, and 12 months, assessing lung function (FEV1), sweat chloride levels, body mass index (BMI), quality of life, medication satisfaction, ear, nose and throat (ENT) symptoms, and physical activity. A control group of four pwCF with classic symptoms and no ETI treatment was included. Results: FEV1 improved significantly after 3 and 6 months (p &lt; 0.05) and stabilized by 12 months. Sweat chloride levels decreased significantly, with four pwCF achieving levels &lt;60 mmol\/L. Improvements in the upper and lower airway symptoms, medication satisfaction, and increased BMI were noted. Conclusions: ETI demonstrates high efficacy in this small group of pwCF with rare CFTR mutations, offering a treatment option that warrants further monitoring and evaluation.<\/jats:p>","DOI":"10.3390\/arm92060049","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T09:48:58Z","timestamp":1735033738000},"page":"559-572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor\/Tezacaftor\/Ivacaftor (ETI)"],"prefix":"10.3390","volume":"92","author":[{"given":"Tomke","family":"S\u00fctering","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-3312","authenticated-orcid":false,"given":"Sebastian F. N.","family":"Bode","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainald","family":"Fischer","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center Munich West, Ludwig Maximilian University (LMU), 81241 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-8101","authenticated-orcid":false,"given":"Dorit","family":"Fabricius","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"unstructured":"N\u00e4hrlich, L., Burkhart, M., and Wosniok, J. (2024, July 08). German Cystic Fibrosis Registry Annual Report. Available online: https:\/\/www.muko.info\/fileadmin\/user_upload\/was_wir_tun\/register\/berichtsbaende\/annual_report_2022.pdf.","key":"ref_3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00127-022-02307-w","article-title":"Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: A systematic review and meta-analysis","volume":"58","author":"Lord","year":"2023","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"unstructured":"N\u00e4hrlich, L., Burkhart, M., and Wosniok, J. (2024, September 20). German Cystic Fibrosis Registry Annual Report. Available online: https:\/\/www.muko.info\/fileadmin\/user_upload\/was_wir_tun\/register\/berichtsbaende\/annual_report_2019.pdf.","key":"ref_9"},{"doi-asserted-by":"crossref","unstructured":"Gruber, W., Stehling, F., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F., Koerner-Rettberg, C., Sutharsan, S., Mellies, U., and Taube, C. (2024). Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor. Front. Sports Act. Living, 6.","key":"ref_10","DOI":"10.3389\/fspor.2024.1284878"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"Overdevest","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/alr.22716","article-title":"Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis","volume":"11","author":"Douglas","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","volume":"280","author":"Bode","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: Healthcare providers\u2019 observations across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr. Pulmonol."},{"doi-asserted-by":"crossref","unstructured":"Piehler, L., Thalemann, R., Lehmann, C., Thee, S., R\u00f6hmel, J., Syunyaeva, Z., Stahl, M., Mall, M.A., and Graeber, S.Y. (2023). Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis. Front. Pharmacol., 14.","key":"ref_18","DOI":"10.3389\/fphar.2023.1179208"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor Treatment and Depression-related Events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"unstructured":"Food and Drug Administration (2024, August 16). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf.","key":"ref_20"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration\u2019s Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","first-page":"101938","article-title":"Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease","volume":"46","author":"Leung","year":"2023","journal-title":"Respir. Med. Case Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pulmoe.2024.03.001","article-title":"Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants","volume":"30","author":"Pinto","year":"2024","journal-title":"Pulmonology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00405-021-07019-6","article-title":"Cross-cultural adaptation and validation of the 22-item sinonasal outcome test (SNOT-22) in German-speaking patients: A prospective, multicenter cohort study","volume":"279","author":"Albrecht","year":"2022","journal-title":"Eur Arch Oto-Rhino-Laryngol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1022037320039","article-title":"Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients","volume":"12","author":"Henry","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcf.2012.04.007","article-title":"Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis","volume":"11","author":"Regnault","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_30","first-page":"60","article-title":"Messung der Bewegungs- und Sportaktivit\u00e4t mit dem BSA-Fragebogen","volume":"23","author":"Fuchs","year":"2015","journal-title":"Eur. J. Health Psychol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr. Pulmonol."},{"doi-asserted-by":"crossref","unstructured":"Stastna, N., Hrabovska, L., Homolka, P., Homola, L., Svoboda, M., Brat, K., and Fila, L. (2024). The long-term effect of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: A pilot observational study. BMC Pulm. Med., 24.","key":"ref_33","DOI":"10.1186\/s12890-024-03069-8"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/92\/6\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:49Z","timestamp":1760115409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/92\/6\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["arm92060049"],"URL":"https:\/\/doi.org\/10.3390\/arm92060049","relation":{},"ISSN":["2543-6031"],"issn-type":[{"type":"electronic","value":"2543-6031"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}